Ovarian Cancer Drugs

Ovarian Cancer Drugs


Global Ovarian Cancer Drugs Market to Reach US$4.8 Billion by 2030

The global market for Ovarian Cancer Drugs estimated at US$3.5 Billion in the year 2023, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Hormonal Therapy segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$949.5 Million While China is Forecast to Grow at 7.8% CAGR

The Ovarian Cancer Drugs market in the U.S. is estimated at US$949.5 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$991.3 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Ovarian Cancer Drugs Market - Key Trends and Drivers Summarized

Ovarian cancer is one of the most challenging gynecological cancers to treat due to its typically late diagnosis and the complexity of its progression. The primary treatment modalities for ovarian cancer include surgery, chemotherapy, targeted therapy, and, more recently, immunotherapy. Traditional chemotherapy, involving drugs such as paclitaxel and carboplatin, remains a cornerstone of treatment, often administered after surgical debulking to eliminate residual cancer cells. These drugs, while effective, come with significant side effects and the risk of developing drug resistance over time. Targeted therapies have emerged as a significant advancement in the treatment of ovarian cancer, with drugs like bevacizumab (an angiogenesis inhibitor) and PARP inhibitors (such as olaparib, niraparib, and rucaparib) offering more tailored approaches. These therapies specifically target cancer cell mechanisms, providing benefits in terms of efficacy and reduced toxicity compared to traditional chemotherapy.

The advent of targeted therapies has revolutionized the landscape of ovarian cancer treatment. PARP inhibitors, in particular, have shown remarkable success in patients with BRCA1 or BRCA2 mutations, as well as in those with homologous recombination deficiency (HRD). These drugs work by exploiting the DNA repair weaknesses in cancer cells, leading to cell death while sparing normal cells. Bevacizumab, on the other hand, inhibits the growth of blood vessels that supply the tumor, effectively starving the cancer cells. Additionally, immunotherapy is making strides with agents like pembrolizumab showing promise in clinical trials. Despite these advancements, the management of ovarian cancer remains complex, with a high recurrence rate necessitating ongoing treatment and monitoring. Research continues to focus on understanding the molecular and genetic underpinnings of the disease to develop more effective and personalized treatment options.

The growth in the ovarian cancer drugs market is driven by several factors. Increasing awareness and early diagnosis through advanced screening techniques are expanding the patient pool eligible for treatment. Technological advancements in genomics and molecular biology are facilitating the development of targeted therapies and personalized medicine, which are proving to be more effective and have fewer side effects. The substantial investment in research and development by pharmaceutical companies is leading to a robust pipeline of new drugs and combination therapies. Regulatory incentives and expedited approval processes for drugs targeting rare and aggressive cancers are also propelling market growth. Additionally, the rising incidence of ovarian cancer globally, coupled with an aging population, is increasing the demand for effective treatments. Collaborations between academic institutions, research organizations, and pharmaceutical companies are fostering innovation and expediting the translation of research into clinical practice. As these trends continue to evolve, the ovarian cancer drugs market is poised for significant growth, driven by the need for better therapeutic options and the ongoing advancements in cancer treatment.

Select Competitors (Total 86 Featured) -
  • AbbVie, Inc.
  • Acrivon Therapeutics
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GSK PLC
  • ImmunoGen, Inc.
  • Imvax
  • Merck & Co., Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Taiho Pharmaceutical Co., Ltd.
  • Vivesto AB
  • Zymeworks, Inc.;
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Global Economic Update
Ovarian Cancer Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Awareness and Early Diagnosis Expand Addressable Market Opportunity
Advances in Genomic and Molecular Biology Propel Development of Targeted Therapies
Rising Incidence of Ovarian Cancer Drives Demand for Effective Treatments
Development of Personalized Medicine Strengthens Business Case for Novel Therapies
Growing Adoption of PARP Inhibitors and Other Targeted Therapies Spurs Market Expansion
Integration of Immunotherapy in Treatment Protocols Throws Spotlight on Innovative Approaches
Expansion of Clinical Trials for Combination Therapies Drives Market Growth
Enhanced Screening Techniques and Diagnostic Tools Accelerate Early Detection
Rising Healthcare Expenditure and Improved Access to Treatments Expand Market Reach
Growing Focus on Reducing Side Effects and Improving Quality of Life Propels Demand for Advanced Therapies
Focus on Overcoming Drug Resistance Generates Opportunities for New Treatments
Market Penetration in Emerging Economies Propels Growth
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Ovarian Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Ovarian Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Ovarian Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Hospital Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Retail Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Online Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: USA Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: USA 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Canada 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
JAPAN
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Japan 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
CHINA
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: China Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: China 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
EUROPE
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Ovarian Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Europe 16-Year Perspective for Ovarian Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
FRANCE
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 59: France Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: France Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: France 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
GERMANY
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 65: Germany Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Germany 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Italy 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
UNITED KINGDOM
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 77: UK Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: UK Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: UK 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
SPAIN
TABLE 83: Spain Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Spain 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 86: Spain Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Spain 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
RUSSIA
TABLE 89: Russia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Russia 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 92: Russia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Russia 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Rest of Europe 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Ovarian Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Ovarian Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
AUSTRALIA
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 110: Australia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Australia Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Australia 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 113: Australia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Australia 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
INDIA
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 116: India Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: India Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: India 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 119: India Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: India 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 122: South Korea Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: South Korea Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: South Korea 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 125: South Korea Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Rest of Asia-Pacific Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
LATIN AMERICA
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 134: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Ovarian Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Latin America 16-Year Perspective for Ovarian Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 137: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 143: Argentina Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Argentina Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Argentina 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 146: Argentina Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
BRAZIL
TABLE 149: Brazil Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Brazil Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Brazil 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 152: Brazil Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
MEXICO
TABLE 155: Mexico Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Mexico Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Mexico 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 158: Mexico Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Rest of Latin America Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Rest of Latin America 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
MIDDLE EAST
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 167: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for Ovarian Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Middle East 16-Year Perspective for Ovarian Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 170: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
IRAN
TABLE 176: Iran Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Iran Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Iran 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 179: Iran Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Iran 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
ISRAEL
TABLE 182: Israel Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Israel Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Israel 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 185: Israel Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Israel 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Saudi Arabia Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Saudi Arabia 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 194: UAE Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: UAE Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: UAE 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 197: UAE Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: UAE 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Rest of Middle East Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Rest of Middle East 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
AFRICA
Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 206: Africa Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Africa Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Africa 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
TABLE 209: Africa Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Africa 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings